ALNY

Business Context and Reporting Period

Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: Alnylam is an early-stage biopharmaceutical company developing therapeutics based on RNA interference (RNAi) technology. The company has not yet received regulatory approval for any products and has incurred significant losses since its inception in June 2002. As of the reporting date, the company had an accumulated deficit of $91.4 million.

Key Financial Metrics

Cash Flow (Nine Months Ended Sep 30, 2005):
- Net cash used in operating activities: $(20,101)
- Net cash provided by investing activities: $6,796 (primarily from sales of marketable securities)
- Net cash provided by financing activities: $466

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 3.4% for the three months ended September 30, 2005, compared to the same period in 2004 ($1.41M vs. $1.37M). For the nine-month period, revenues increased significantly to $4.16M from $1.63M in 2004, driven by cost reimbursement revenues from the Merck collaboration and license fee amortization.
• Expense Increases: Total operating expenses rose 55% for the quarter ($12.1M vs. $7.8M) and 15% for the nine-month period ($32.7M vs. $28.4M).
  • R&D Expenses: Increased 65% for the quarter and 16% for the nine months. The quarterly increase was driven by higher non-cash stock-based compensation, external services for the RSV and AMD programs, and license fees.
  • G&A Expenses: Increased 38% for the quarter and 14% for the nine months, primarily due to consulting/professional services for business development and Sarbanes-Oxley compliance, and increased stock-based compensation.
• Liquidity Position: Cash and cash equivalents decreased from $20.3 million at December 31, 2004, to $7.2 million at September 30, 2005. Total liquid assets (cash + marketable securities) declined from $46.0 million to $24.8 million.

Guidance, Outlook, and Material Events

Strategic Collaboration with Novartis: In October 2005 (post-period end), Alnylam entered into a significant collaboration with Novartis. Novartis purchased 5.27 million shares of common stock for approximately $58.5 million and executed a research collaboration and license agreement. Novartis made up-front payments of $10.0 million. This agreement is expected to provide substantial funding and access to technical resources.

Program Updates:

• RSV Program: The company submitted an Investigational New Drug (IND) application to the FDA in November 2005 for ALN-RSV01, expecting to initiate human clinical trials before the end of 2005.
• AMD Program: In September 2005, the company suspended further development of its VEGF program for age-related macular degeneration (AMD) due to competitive landscape and commercial factors, though the collaboration with Merck on other ocular targets continues.

Outlook and Risks:

• The company expects to incur significant additional losses over the next several years as it expands R&D activities.
• Management believes existing resources, combined with expected cash from alliances (including Novartis), will fund operations beyond the end of 2006.
• Accounting Change: The company will adopt SFAS 123R (Share-Based Payment) in the first quarter of 2006, which is expected to materially increase stock compensation expense.
• Patent Risks: Key patents (Kreutzer-Limmer series) are subject to opposition proceedings in the European and Australian Patent Offices, which could result in invalidation.

Key Facts for Investor Verification

• Liquidity Runway: Verify the sufficiency of the $24.8 million in liquid assets to fund operations through 2006, considering the high burn rate (approx. $20M cash used in operations for the first nine months of 2005).
• Novartis Deal Terms: Confirm the specific milestone payments, royalty rates, and the "Integration Option" details within the October 2005 Novartis agreement, as these will drive future revenue.
• RSV Clinical Trial Timeline: Monitor the initiation of the RSV clinical trials expected in late 2005, as this is the first major step toward product commercialization.
• Stock-Based Compensation Impact: Assess the financial impact of the upcoming adoption of SFAS 123R in Q1 2006, which will likely increase reported net losses.
• Patent Opposition Status: Track the outcome of the opposition proceedings against the Kreutzer-Limmer patents in Europe and Australia, as these are critical to the company's IP portfolio.